bioequivalence of potassium chloride tablets, and we've also found that the correction method as proposed in the guidance for industry is reproducible during the two study periods. We found that baseline-corrected data are more sensitive to differences in formulation performance than uncorrected data. We've also found that baseline correction can make a difference in whether a product passes or does not pass the 90 percent confidence interval criteria, and finally, we found that although it was essential to do a baseline correction of the two methods that we tested, the method did not affect the study outcome.
Thank you very much, and now Dr. Conner will summarize this afternoon's presentation on bioavailability and bioequivalence of endogenous substances.
DR. CONNER: Again, to restate some of the technical problems or questions or, I guess you could say, controversial issues with endogenous substances in general, some of the things that we've discussed or seen illustrated are assay sensitivity. If you have a very small amount of something, especially after baseline correction, it's important to be able to give your assay